, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Conferring "drug like properties" on active compounds to create a drug lead that is active in-vivo
Life Sciences and Biotechnology, Medicine
Biopharmaceutics of Drug Development Laboratory, The Institute for Drug Research,
School of Pharmacy
Selection of potential drug candidates, using in vitro and in vivo models to overcome drawbacks that only become apparent when transferring an active in vitro compound to animals
Conferring "drug-like properties" on active molecules (mainly peptides) by making them stable and orally available while maintaining their activity
Identifying the absorption barriers of drugs (drug candidates) that manifest poor bioavailability
Identifying absorption windows along the GI tract
Biopharmaceutical assessment of novel drug delivery systems
Enhancing bioavailability of highly lipophilic drugs: e.g. lipolysis model, lymphatic absorption of drugs
The lab uses a battery of screening processes and employs a unique methodology based on a pharmacodynamic/pharmacokinetic characterization to formulate the drug and ensure it reaches the correct target at the right time and in the right concentrations. After screening, drugs are tested in freely moving rats to understand how they behave in a normal physiological environment.
The lab has intensive experience in clinical and preclinical pharmacokinetic research with particular focus on the rational selection of an optimized drug delivery system. Currently, the lab focuses on three main directions:
Turning active peptides into drugs
Improving the bioavailability of lipophilic drugs
Developing controlled release drug delivery systems for use in animals and humans
Researcher and Research Interests
Professor Amnon Hoffman, Chairman, Division of Clinical Pharmacy; Head, Pharm. D. Program, School of Pharmacy. In addition to his research activities, Professor Hoffman is involved in the academic side of the School of Pharmacy, training new drug researchers and pharmacists in the clinical aspects of pharmacotherapy and applied pharmacokinetics. Professor Hoffman has over 20 years of experience in the field of pharmacokinetics and pharmacodynamics, with a special interest in the biological aspects of drug delivery systems. He also has extensive training and background in the development of novel sustained release drug delivery systems, including a new technology called Gastro-retentive Dosage Form (GRDF). He has published widely and is the scientific co-founder of the startup companies Intec Pharma and Active PX.
Professor Hoffman's lab is fully equipped for in vitro, ex vivo and in vivo assessments of the activities described above.
Professor Amnon Hoffman, firstname.lastname@example.org, +972-2-675-7014